Photoreceptor cell death is the ultimate cause of vision loss in many retinal disorders, and there is an 1 7 unmet need for neuroprotective modalities to improve photoreceptor survival. Similar to cancer cells,
catalyzed reaction ( Fig. 6a-c) . The ratio of intracellular PEP to pyruvate was statistically significantly 0 3 decreased in the ML-265 treated cells (Fig. 6d) , which further demonstrates the ability of ML-265 to 0 4 activate PKM2 as PEP is a substrate of this enzyme and pyruvate a product. Consistent with 0 5 previous studies, a decrease in the intracellular concentrations of ribose 5-phosphate (R5P) and 0 6 serine (Ser) were also observed ( Fig. 6b and c) . 21 R5P is involved in the biosynthesis of nucleotides the synthesis of other amino acids and phospholipids, and donates carbon to the folate cycle. 31 1 0 Therefore, these data indicate that ML-265-mediated activation of PKM2 can alter glucose 1 1 1 0 metabolism to produce a more catabolic state. Notably, similar alterations in metabolite pools were 1 2 not evident in the retinas with PKM1-expressing rod photoreceptors (Rho-Cre:Pkm2 f/f ) (Fig. 6e ). In 1 3 these retinas, relative to control retinas where both rod Pkm2 alleles are present (Rho-Cre:Pkm2 +/+ ), 1 4 there was a statistically significant increase in 2-PG and a trend towards increased PEP, consistent 1 5 with previous metabolic flux studies. 12 1 6 1 7 ML-265 treatment circumvents apoptosis and prevents cell death in vitro. Next, we wanted to 1 8 investigate the role of pharmacologic activation of PKM2 and the associated metabolic alterations as 1 9 a novel photoreceptor neuroprotection strategy using a disease-relevant, in vitro model. Previous 2 0 studies have shown that Fas signaling plays a crucial role in caspase activation and photoreceptor 2 1 apoptosis in vivo after retinal detachment. 32,33 661W cells undergo caspase-mediated cell 2 2 death, 25, 27, 34 and treatment of 661W cells with Fas-ligand (FasL) has been shown to lead to caspase 2 3 activation and cell death similar to that observed after experimental retinal detachment, making this a 2 4 good in vitro model of outer retinal stress. 15, 35 As such, 661W cells were treated with FasL and either treated with FasL alone, a statistically significantly increase in both caspase 8 and 3&7 activation was 2 8 observed as well as a decrease in cell viability, as has been shown previously . 35,36 2 9 Treatment with ML-265 significantly decreased caspase 8 and 3&7 activation in the presence of FasL 3 0 ( Fig. 7a and b ). In agreement with this effect on caspase activation, ML-265 treatment of 661W cells 3 1 significantly increased cell viability as compared to vehicle in the presence of FasL (Fig. 7c ). These 
ML-265 treatment decreases apoptosis in vivo.
We have previously shown that Rho-Cre:Pkm2 f/f 1 1 entrance into the apoptosis cascade and improved photoreceptor survival in an experimental model 3 8 of retinal detachment. 15 Additionally, the in vitro data above suggests that ML-265 is capable of 3 9
reducing Fas-mediated caspase activation. Therefore, we hypothesized that ML-265-mediated 4 0 activation of PKM2 would circumvent apoptosis in a similar in vivo experimental model of retinal 4 1 detachment in rats. 32, 33 Photoreceptor apoptosis in these experimental retinal detachments is 4 2 associated with caspase activation, which has been shown to increase 3 days after detachment, and retinal detachment. 32, 35, 37 Thus, rat retinas were detached, different concentrations of ML-265 or its 4 5 vehicle, DMSO, were injected at the time of detachment, and the retinas were harvested after 3 days manner as compared to DMSO treated eyes ( Fig. 8a) . Likewise, ML-265 statistically significantly 4 9 reduced caspase 3/7 activation at the two higher doses tested as compared to DMSO (Fig. 8b) . In this study, we show that ML-265 is capable of increasing total PK activity in vitro in the 661W cell 5 3 culture model as well as in vivo in rat retinas. ML-265 has a relatively long half-life in the eye following 5 4 intravitreal injection and remains active at least two weeks after injection. Extended exposure to ML-5 5 265 had no effect on photoreceptor function or survival under baseline conditions compared to 5 6 vehicle-treated eyes. Interestingly, ML-265 increased PK activity without affecting the expression of 5 7 genes involved in glucose metabolism. ML-265 treatment did, however, alter glucose metabolism to 5 8 produce a more catabolic state. Notably, ML-265-mediated PKM2 activation reduced entrance into suggest that pharmacologic reprogramming of photoreceptor metabolism by PKM2 activators may be 6 1 a novel neuroprotective strategy. Previous studies from our laboratory and others generated and characterized a rod photoreceptor- demonstrated no significant differences in the ONL but observed that loss of PKM2 in the 6 7 photoreceptors of their mice reduced the thickness of the photoreceptor end tips at 5 months of age. 12 6 8
We observed small degenerative changes in outer retinal thickness and ONL cell count and area to 5 months to present, the in vivo electroporation studies with PKM1-expressing constructs would go 7 7 against this postulation. Reports have shown that PKM1 and PKM2 have different cellular functions, 7 8 and these different actions may not be limited to their well-described glycolytic functions. 24, 38, 39 For 7 9 example, some studies have suggested that PKM2 can translocate to the nucleus. 23, 40, 41 Another 8 0 study has shown that PKM2 has a unique effect on mitochondrial biogenesis and activation of PKM2 8 1 improves mitochondrial dysfunction. 24 Also, PKM2 is regulated by glucose metabolites and cellular 8 2 signaling processes. 18 Therefore, compensatory increase in PKM1 expression and PK activity may 8 3 not be equivalent to PKM2 activation in photoreceptors. Further studies are required to probe these 8 4 different cellular functions in photoreceptors. activator, no differences in scotopic or photopic electroretinography amplitudes were noted between 8 9 1 3 the ML-265 and vehicle treated eyes (Fig. 4 ). The differences in retinal function, as assessed by 9 0 electroretinography, between pharmacologic activation of PKM2 and genetic isoform reprogramming 9 1 in the mouse model may again be due to the fact that injections were only given over the course of 6 9 2 weeks and significant differences in electroretinography amplitudes were not observed until after 5 9 3 months of age in the Rho-Cre:Pkm2 f/f mice. Yet, another possible explanation for the lack of 9 4 differences between the ML-265 and vehicle treated eyes is that any small changes in retinal function retinal function for concentrations of 0.6% or more. 42 The low aqueous solubility of ML-265 (29.6 9 8 μg/mL) necessitates the use of organic solvents to achieve sufficient drug concentrations in the 9 9
vitreous cavity due to the limiting injection volumes (2 μL). 43 An average vitreous volume of 15 μL in 0 0 rats was assumed in this study. 44, 45 Even with these low injection volumes, the retina was exposed to functional analyses performed in this study. Future studies are needed to address this issue as 1 0 developing novel PKM2 activators with improved solubility will be ideal for intraocular delivery. Regardless, this study shows that pharmacologic activation of PKM2 by ML-265 increases 1 3 photoreceptor resistance to apoptotic stress. Activation of PKM2 may allow the cell to optimize ATP 1 4 1 4 production in the face of outer retinal stress by increasing flux through glycolysis and ultimately, shifting metabolism from an anabolic to more catabolic state as observed in this study and others. 21,24 1 6
Notably, pharmacologic activation of PKM2 with this small molecule has also been shown to 1 7 circumvent cellular apoptosis in other disease models, and it is postulated that PKM2 activation 1 8 achieves this effect by reducing mitochondrial dysfunction and increasing mitochondrial biogenesis 1 9 via different pathways. 24 Furthermore, the ability of ML-265-mediated activation of PKM2 to 2 0 circumvent photoreceptor apoptosis in vivo is in accordance with our previous results that showed Additionally, ML-265 treatment in vitro resulted in decreased pools of glycolytic metabolites directly 3 1 upstream of PKM2 as well as those of ribose 5-phosphate and serine, which suggests a more 3 2 catabolic cellular state (Fig. 6b ). Activator treatment in H1299 cells demonstrated analogous changes 3 3 in the key biosynthetic intermediates, ribose 5-phosphate and serine. 21 However, changes in these 3 4 metabolite pools in the retinas of Rho-Cre:Pkm2 f/f mice differed from that of ML-265 treatment with 2-3 5 PG being statistically significantly increased and PEP demonstrating a similar trend (Fig. 6d ).
6
Understandably, the alterations in the metabolite pools from the Rho-Cre:Pkm2 f/f mice are 1 5 states may reflect that PKM1 expression in photoreceptors leads to adaptive changes to compensate 4 1 for the chronically elevated PK activity, unlike transient activation of PKM2 with In summary, we have shown that ML-265-mediated PKM2 activation and its corresponding metabolic degenerations. 4, 11, 49 This study coupled with our previous work that genetically increased the levels of 5 2 activated PKM in photoreceptors gives credence to this therapeutic strategy. 15 However, further 5 3 studies are needed to not only circumvent the solubility issues that limit the translation of ML-265 into 5 4 the clinic but also to obtain mechanistic insight into the differential actions of PKM1 and PKM2 in 5 5 photoreceptor metabolism, function, and viability. humidified atmosphere of 5% CO 2 and 95% air. HCl (pH 7.4), 100 mM KCl, and 5 mM MgCl 2 as previously described. 15, 17 The decrease in 8 9 absorbance at 340 nm was monitored using a SPECTROstar Omega plate reader (BMG LABTECH 9 0
Inc., Cary, NC, USA). Initial velocities were calculated with the MARS software. Data were 9 1 normalized to DMSO (dimethyl sulfoxide)-treated PKM2 activity. Cell culture. For 661W cell line experiments, media was replaced prior to the start of treatment with 9 4 DMSO or ML-265. Cells were incubated with DMSO or different concentrations of ML-265 for 2 hours. Diagnostics, Indianapolis, IN) and cellular debris was removed by centrifugation at 10,000 rpm for 10 9 8 minutes. Ten microliters of the supernatant was used to assess pyruvate kinase activity, and the 9 9
activity was normalized to total protein content as previously described. 22 utilized as it has been shown to produce minimal reflux, and lower volumes may not produce 0 9 adequate reproducibility. 44, 45 An average vitreous volume in rats of 15 μL was assumed in order to 1 0 estimate intravitreal concentrations of ML-265 after injection throughout this study. 44, 45 Left eyes were 1 1 injected with ML-265, and right eyes were injected with DMSO, which served as the control that 1 2 pyruvate kinase activation was based upon. Four hours after intravitreal injection, retinas from and Extraction Buffer with protease inhibitors. The assay was carried out using 4 microliters of rat described. 15, 17 Pyruvate kinase activity was normalized to total protein in each retinal lysate. Quantitative Real-Time PCR. 661W cells were grown to 70% confluency at 37 °C in a humidified 2 0 atmosphere of 5% CO 2 and 95% air in Dulbecco's modified Eagle's medium containing 25 mM media also contained penicillin (90 units/mL) and streptomycin (0.09 mg/mL). One day prior to the 2 4 start of treatment, the media was replaced with fresh media containing 5.5 mM glucose. Treatment was started by replacing the media with fresh media containing 5.5 mM glucose and DMSO or 2 µM 2 6 ML-265, and the respective media was replaced with fresh media every day. Cells were harvested 2 7 after 3 days of treatment. Intravitreal injections of ML-265 or DMSO were performed in Brown-Norway, adult rats as described Total RNA was purified from retinal tissues of rats and 661W cells as previously described. 15 3 6
Quantitative PCR was performed using the Rat Glucose Metabolism RT 2 Profiler™ PCR Array normalized to the housekeeping genes Actb, B2m, and Rplp1 in rats and Actb, B2m, and Gusb in 4 3 661W cells. initiation of treatment, the media was changed to DMEM with 5.5 mM glucose, 4 mM glutamine, 10% 5 0 fetal bovine serum, and without sodium pyruvate. At t=0, the media was refreshed, and the cells were 
